Correlation between Serum LP-PLA2 and sST2 Levels and the Condition of Patients with Acute Heart Failure and Their Prognostic Value

Abstract

Acute heart failure (AHF) occurs mostly in the elderly, which is a syndrome that occurs in the later stages of the development of cardiovascular disease. Due to the sharp decline in the patient’s heart function, the patient has a high mortality rate and a poor prognosis, which seriously threaten the life safety of the elderly. Therefore, early diagnosis of AHF and timely treatment are extremely important. Lipoprotein-associated phospholipase A2 (LP-PLA2) is a newly discovered cardiovascular-specific inflammatory marker, which is closely related to the formation and progression of atherosclerotic plaque and the occurrence and development of coronary heart disease. Soluble growth stimulation expression gene 2 (sST2) protein is a protein produced under the induction of mechanical stress in cardiomyocytes. It can act as a decoy receptor to mediate the interleukin-33 (IL-33)/ST2 signaling pathway to bind to IL-33, thereby reducing the myocardial protective effect and leading to myocardial remodeling. The purpose of this study was to explore the serum LP-PLA2 and sST2 levels in AHF patients and to analyze their correlation with the disease and their prognostic value. The results showed that the levels of serum LP-PLA2 and sST2 were increased in AHF patients, and the levels of serum LP-PLA2 and sST2 in patients with adverse prognostic events were higher than those in patients without adverse prognostic events. The levels of serum LP-PLA2 and sST2 are closely related to the degree of patients’ illness, among which the combined prediction of AHF patients with LP-PLA2 and sST2 has the highest value, which is worthy of promotion.

Correlations between soluble ST2 concentration and the nutritional status in patients with heart failure with reduced ejection fraction — cross-sectional study

“…Soluble ST2 (sST2) acts as a decoy receptor, directly bound to IL-33, and suppresses activation of JNK (c-Jun N-terminal kinase), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and ERK (extracellular signalregulated kinases), reversing the beneficial effects of the IL-33/ST2 system, thus destabilizing the defense mechanism. The association between sST2 and mortality rates was confirmed in patients with acute [10][11][12][13], chronic decompensated [14] and chronic HF [3,15,16]. Moreover, the association was observed regardless of the left ventricular ejection fraction (LVEF) values, as well as in patients with reduced ejection fraction (HFrEF) [3,17,18].…”

sST2 and Heart Failure—Clinical Utility and Prognosis

“…In recent years, studies on the use of sST2 protein as a biomarker in acute and chronic HF have been published. In recent years, studies have been published on the usefulness of the sST2 as a biomarker in acute [9] and chronic decompensated HF [10].…”

Retracted: Correlation between Serum LP‐PLA2 and sST2 Levels and the Condition of Patients with Acute Heart Failure and Their Prognostic Value

“…Tis article has been retracted by Hindawi following an investigation undertaken by the publisher [1]. Tis investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process:…”

“…This article has been retracted by Hindawi following an investigation undertaken by the publisher [ 1 ]. This investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process: Discrepancies in scope Discrepancies in the description of the research reported Discrepancies between the availability of data and the research described Inappropriate citations Incoherent, meaningless and/or irrelevant content included in the article Peer-review manipulation …”